NTAP
67
-3
NRG
49
-3
URBN
56
14
HD
57
2
BMY
60
2
CSCO
67
4
GPC
40
3
EQT
57
-2
CSX
60
3
A
43
2
ORLY
62
2
ROP
62
3
TXT
55
3
PG
56
5
AA
48
-12
LB
63
22
EL
25
4
CF
57
-2
BAC
53
3
MLM
57
6
NTAP
67
-3
NRG
49
-3
URBN
56
14
HD
57
2
BMY
60
2
CSCO
67
4
GPC
40
3
EQT
57
-2
CSX
60
3
A
43
2
ORLY
62
2
ROP
62
3
TXT
55
3
PG
56
5
AA
48
-12
LB
63
22
EL
25
4
CF
57
-2
BAC
53
3
MLM
57
6
Financhill
Back

Protalix BioTherapeutics 10K Form

Buy
79

PLX
Protalix BioTherapeutics

Last Price:
1.70
Seasonality Move:
86.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PLX News And Ratings

See the #1 stock for the next 7 days that we like better than PLX

PLX Financial Statistics

Sales & Book Value

Annual Sales: $65.49M
Cash Flow: $4.02M
Price / Cash Flow: 18.51
Annual Sales: $0.44
Price / Book: 3.84

Profitability

EPS (TTM): -0.16000
Net Income (TTM): $-9.61M
Gross Margin: $42.51M
Return on Equity: -29.54%
Return on Assets: -11.58%

Protalix BioTherapeutics Earnings Forecast

Key Protalix BioTherapeutics Financial Ratios

  • The Gross Profit Margin over the past 26 years for PLX is 64.91%.
  • The Selling, General & Administrative Expenses for PLX have been equal to 22.84% of Gross Profit Margin.
  • The Research & Development expenses have been 26.10% of Revenue.
  • The Interest Expense is 38.26% of Operating Income.
  • The Net Earning history of PLX is 12.69% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 13 years.

Protalix BioTherapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: PLX
CUSIP: 74365A
Website: protalix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.98
Quick Ratio: 1.22

Price-to-Earnings

Trailing P/E Ratio: 18.78
Forward P/E Ratio: 0

PLX Technical Analysis vs Fundamental Analysis

Buy
79
Protalix BioTherapeutics (PLX) is a Buy

Is Protalix BioTherapeutics a Buy or a Sell?